Blockchain Registration Transaction Record

Regentis Biomaterials Gets Approval for Next-Gen GelrinC Manufacturing

Regentis Biomaterials receives European approval for next-gen solvent-free GelrinC manufacturing, boosting yield by 400%. GelrinC is a cell-free hydrogel for cartilage repair targeting a $3B US market. Read more.

This milestone matters because it dramatically increases production capacity for GelrinC, a novel cartilage repair treatment that could offer a minimally invasive solution for the hundreds of thousands of patients suffering from knee cartilage damage. With no off-the-shelf alternatives currently available, this advancement brings Regentis closer to commercializing a therapy that may improve quality of life and reduce the need for more invasive surgeries, potentially transforming the orthopedic landscape.